Volume | 6,186,586 |
|
|||||
News | - | ||||||
Day High | 15.18 | Low High |
|||||
Day Low | 14.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
14.12 | 14.10 | 15.18 | 14.82 | 14.10 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
36,034 | 6,186,586 | $ 14.77 | $ 91,360,879 | - | 3.21 - 18.33 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:12:31 | 3 | $ 14.90 | USD |
Iovance Biotherapeutics (IOVA) Options Flow Summary
Iovance Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.13B | 279.31M | - | 1.19M | -444.04M | -1.59 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Iovance Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.04 | 15.90 | 13.75 | 14.68 | 4,952,644 | -0.14 | -0.93% |
1 Month | 16.83 | 18.24 | 13.60 | 15.36 | 8,232,008 | -1.93 | -11.47% |
3 Months | 7.93 | 18.33 | 7.34 | 12.87 | 9,947,933 | 6.97 | 87.89% |
6 Months | 4.48 | 18.33 | 3.21 | 9.60 | 8,478,886 | 10.42 | 232.59% |
1 Year | 6.11 | 18.33 | 3.21 | 8.51 | 7,102,866 | 8.79 | 143.86% |
3 Years | 28.28 | 33.99 | 3.21 | 10.89 | 4,406,227 | -13.38 | -47.31% |
5 Years | 9.41 | 54.2081 | 3.21 | 14.33 | 3,255,907 | 5.49 | 58.34% |
Iovance Biotherapeutics Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. |